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Abstract
Purpose To evaluate the role of methotrexate
(MTX) injected into the silicone oil at the end
of pars plana vitrectomy for advanced
proliferative diabetic retinopathy (PDR).
Methods In this prospective comparative
interventional study, eyes with severe
diabetic tractional macular detachment or
combined tractional/rhegmatogenous retinal
detachment were included. Standard 20 gauge
pars plana vitrectomy, and retinal
reattachment was performed. In the case
group, 250 μg MTX was injected into the
silicone oil at the end of surgery. The rate of
retinal re-detachment associated with
fibrovascular proliferation or proliferative
vitreoretinopathy (PVR) was assessed.
Results Overall, 38 eyes of 35 patients
(19 cases and 19 controls) were studied. The
two groups were matched for age, sex,
preoperative visual acuity, and the type of
surgery (vitrectomy alone vs combined
phacoemulsification/vitrectomy). Retinal
re-detachment with fibrovascular prolifera-
tion or PVR occurred in seven eyes (36.8%) in
the MTX group and eight eyes (42.1%) in the
control group (P=0.74). Mean change in visual
acuity was 0.04± 0.71 and 0.39± 0.70 logMAR
in the MTX and the control group, respectively
(P=0.14). The rate of improvement or
worsening of visual acuity was similar between
the two groups (P=0.51 and P=0.12).
Conclusion Intra-silicone injection of MTX
at the end of vitrectomy for retinal
detachment associated with severe PDR did
not reduce the risk of postoperative retinal
detachment due to the fibrous or fibrovascular
proliferations.
Eye (2015) 29, 1199–1203; doi:10.1038/eye.2015.114;
published online 10 July 2015
Introduction
The Diabetic Retinopathy Vitrectomy Study
defined the benefit of pars plana vitrectomy in
the management of persistent vitreous
hemorrhage, and severe active fibrovascular
proliferation.1 Since then, the indications for
surgical management of advanced proliferative
diabetic retinopathy (PDR) have steadily
evolved.2 Recent tractional macular detachment
(TMD) or macula threatening tractional retinal
detachment (TRD), and combined tractional–
rhegmatogenous retinal detachment (TRD/
RRD) are also currently considered as important
indications for vitreoretinal surgery.2
Although a growing number of eyes with
TMD and TRD/RRD are successfully treated
with a single procedure, retinal re-detachment
associated with fibrovascular proliferation or
proliferative vitreoretinopathy (PVR) is still a
major cause of failure of the surgery.2,3 Previous
studies have shown increased expression of
inflammatory cytokines and growth factors in
both PDR and PVR.4–6 Considering the major
role of inflammatory mediators, it is rational to
consider anti-inflammatory medications as a
potential modality for prevention of
proliferation of post-vitrectomy membranes.
Methotrexate (MTX) is an anti-neoplastic and
anti-inflammatory agent used to treat a variety
of malignancies and rheumatologic diseases.
In ophthalmology, systemic and intraocular
MTX has been successfully used for
indeterminate uveitis, sarcoid uveitis, primary
CNS lymphoma, and non-Hodgkin’s
lymphoma.7,8 Recently, small case series have
reported promising results with intra-silicone
injection of MTX after vitrectomy for advanced
PDR.9,10 The aim of the present study was to
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evaluate the outcome of intra-silicone injection of MTX at
the end of pars plana vitrectomy for eyes with TMD or
TRD/RRD.
Materials and methods
In this prospective comparative interventional study,
from January 2012 to January 2014, all patients who
underwent pars plana vitrectomy for diabetic TMD or
TRD/RRD with broad and diffuse fibrovascular
membrane attachments causing underlying retinal folds
were included. The surgical plane was less clearly defined
in these cases and the surgical procedures were
categorized as major complexity procedures.2 All patients
had retinal breaks before or at the time of surgery
(TRD/RRD). The case group consisted of eyes that
underwent surgery from January 2013 to January 2014.
In this group, intravitreal injection of MTX was performed
at the end of the surgery. All eyes that underwent surgery
from January 2012 to January 2013 were served as
controls. In this group, no MTX injection was performed.
Patients with other intraocular diseases that may affect
the course of the retinal detachment repair including
uveitis, congenital vitreoretinopathies, and those with
traumatic retinal detachment were excluded. Also,
patients with history of previous vitreoretinal procedures
were excluded. Ethics committee of the Iran University
Eye Research Center approved the study. Complexity of
the vitreoretinal problem, and the chance of surgical
failure were explained and informed consents were
obtained.
All patients received intravitreal injection of
bevacizumab (1.25mg/0.05ml) the night before
vitrectomy as described elswhere.11 All surgeries were
performed by one surgeon (KGF). Standard three-port 20
gauge pars plana vitrectomy was performed. The surgical
procedure consisted of segmentation and delamination of
fibrovascular membranes. Also, ‘en bloc’ dissection of
neovascular membranes was performed when possible.
No circumferential episcleral band was inserted. In cases
with significant retinal shortening or unreleasable
contractures, retinotomy or retinectomy was performed.
Silicone oil was used for endotamponade in all eyes.
In the case group, before closure of inflow sclerotomy,
0.1 cc (250 μg) of commercially available MTX solution
(Haupt Pharma Gmbh, Wolfratshausen, Germany) was
injected into the silicone-filled mid-vitreous cavity. At the
conclusion of the surgery, subtenon injection of
triamcinolone acetonide (40mg/1ml) was performed.
On the first postoperative day, topical antibiotic eye drop
was administered four times daily for 2 weeks and topical
betamethasone eye drop was prescribed every 2 h during
the waking hours for 1 week and then four times daily for
the next 2 weeks. The surgical procedure and
postoperative medications were the same for both groups
except for intra-silicone injection of MTX in the
case group.
The patients were visited 1 day, 1 week, 1 month,
3 months, 6 months, and at the last follow-up after
surgery. In patients without recurrent retinal detachment
after surgery, the follow-up was continued for at least
6 months. Primary outcome measure was the rate of
postoperative retinal detachment due to the fibrovascular
proliferation or PVR, and the secondary outcome measure
was the postoperative visual acuity.
Statistical analysis was performed with SPSS software
(IBM Inc., Chicago, IL, USA) and Po0.05 was considered
significant. Paired t-test, independent t-test, Fisher’s exact
test, and χ2-test were used for analysis.
Results
Overall, 38 eyes of 35 patients (19 eyes in each group)
with a mean age of 51.72± 7.55 years were studied.
Table 1 shows demographics of the patients. Baseline
characteristics including age, sex, baseline visual acuity,
and history of cataract surgery were statistically similar
between the two groups. No patient developed retinal
detachment during first postoperative month. Mean
follow-up time was 12.3± 5.3 months.
Characteristics and outcomes of the eyes in the two
groups are summarized in Table 2. Retinal re-detachment
with fibrovascular proliferation or PVR occurred in seven
eyes (36.8%) in the MTX group and eight eyes (42.1%) in
the control group (P= 0.74), all due to the proliferation
of fibrovascular or fibrous membranes. In eyes with
retinal detachment, repeated vitreoretinal surgery was
performed in 3 eyes in MTX group and 4 eyes in
control group. Other patients rejected further surgery.
Final reattachment rate was 78.9% in both groups.
Mean interval between surgery and detection of the
retinal detachment in follow-up visits was
6.00± 3.24 months in the MTX group and
5.48± 4.67 months in the control group (P= 0.93). Silicone
oil was removed from four eyes (21%) in the MTX group
and five eyes (26.3%) in the control group (P= 1).
In MTX groups, the change in visual acuity after
surgery was not statistically significant (P= 0.77);
however, statistically significant improvement was found
in the control group (P= 0.02). Mean change in visual
acuity was 0.04± 0.71 and 0.39± 0.70 LogMAR in MTX
and control group, respectively (P= 0.14). Visual acuity
improved in seven eyes (36.8%) in the MTX group and
nine eyes (47.3%) in controls (P= 0.51). A decrease in
visual acuity was found in seven eyes (36.8%) in the MTX
group and two eyes (10.5%) in the control group
(P= 0.12).
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Discussion
Although many angiogenic and cytokine mediators are
involved in the development and progression of diabetic
retinopathy, inflammatory reaction seems to have a
critical role in the pathophysiology of the diabetic
retinopathy.4 Previous studies have shown a significant
increase in the level of inflammatory mediators such as
ICAM-1, VCAM-1, IL-6, IL-8, IL-10, and TNF-α in PDR.4
Considering the prominent role of inflammation in
pathogenesis of fibrovascular proliferation and PVR,
which are the known complications after diabetic
vitrectomy, the use of anti-inflammatory medications has
been suggested. Previous studies have reported
contradictory results after intravitreal injection of
triamcinolone acetonide in patients undergoing vitrectomy
for PDR.12,13 Jonas et al12 reported a reattachment rate of
89.7% after intravitreal injection of 15–20mg of crystalline
triamcinolone acetonide at the end of surgery in a series of
patients with advanced PDR. However, in a comparative
study, the same group reported similar outcomes between
the intravitreal injection of triamcinolone acetonide and the
control group.13 Moreover, intravitreal injection of steroids
may result in cataract formation and steroid-induced
glaucoma.
MTX is a folate analog and works by inhibiting
dihydrofolate reductase, which is involved in the
synthesis of thymidylate and purine nucleotide, resulting
in the inhibition of rapidly dividing cells such as
lymphocytes. Although MTX was first introduced as an
antiproliferative agent, it is now clear that many of the
anti-inflammatory effects of MTX are mediated by
adenosine.14 Several studies have shown that MTX
modulates the humoral and cellular responses and
suppresses the level and activity of TNF and various
ILs.14,15 Previous studies have reported potent anti-
inflammatory properties of the intravitreal MTX in
patients with noninfectious uveitis.16,17 Moreover,
intravitreal injection of MTX has less complication
compared with the triamcinolone acetonide, another
potent widely used anti-inflammatory agent.9 Two
studies reported the use of intra-silicone MTX for surgical
indications other than intraocular lymphoma.9,10 In these
reports, a total of seven eyes had vitrectomy for diabetic
TRD and TRD/RRD. Visual acuity improved in two eyes,
remained stable in three eyes and decreased in others.
Anatomical outcome was reported for three eyes and the
retina was attached at the end of follow-up in these eyes.
On the whole, the available literature has defined a
positive role for MTX in controlling proliferative
conditions, including inflammatory response such as
postoperative inflammation. However, our study did not
show a beneficial result from its injection at the end of
vitrectomy for prevention of glial proliferation and the
resultant retinal detachment in PDR. This may be ascribed
to several reasons. The sample size was small and may
not have had enough power to detect the difference
between the two groups. Also, therapeutic half-life of
MTX after a single intravitreal injection is only 3–5 days, 18,19
whereas the process of glial proliferation after vitrectomy
has a protracted course and may take several weeks to
months. It is possible that multiple postoperative
injections of MTX over few weeks would prevent
membrane formation more efficiently. Another possibility
is that the slow diffusion of MTX out of the silicone oil
may make its available concentration in the perisilicone
space inadequate for an efficient therapeutic effect.
Previous studies have shown that intravitreal injection of
400 μg of MTX is nontoxic for the retina.8 Also, the safety
of intra-silicone injection of 200 and 400 μg doses of MTX
has been previously tested.9,10 Considering the reduced
clearance in vitrectomized eyes filled with silicone oil, we
selected the lower dose to allay the concerns of toxicity.10
Higher doses of MTX may have better effect while being
still in the safe range.10
Our study has some limitations. The non-randomized
design of study is one the major limitations. The study is
underpowered to detect small differences between the
two groups. Based on our current results, the sample size
needed for a statistical power of 80% to detect a 10%
Table 2 Baseline characteristics and outcomes of diabetic patients with tractional or combined tractional–rhegmatogenous retinal
detachment who underwent pars plana vitrectomy in the methotrexate and control group
MTX group Control group P-value
Number of eyes 19 19
Age (year; mean± SD) 50.61± 8.93 52.83± 5.92 0.38a
Sex (male/female) 6/12 8/10 0.49b
Lens status (phakic/pseudophakic) 17/2 16/3 1c
Surgery (vitrectomy/combined phacoemulsification and vitrectomy) 11/8 12/7 0.74b
Baseline visual acuity (logMAR) (mean± SD) 2.14± 0.76 2.24± 0.65 0.23a
Final visual acuity (logMAR; mean± SD) 2.09± 0.84 1.85± 0.68 0.33a
Change in visual acuity (logMAR; mean± SD) 0.04± 0.71 0.39± 0.70 0.14a
Number of eyes with retinal re-detachment after first vitrectomy 7 8 0.74b
Abbreviation: MTX, methotrexate. a t-test. b χ2-test. c Fisher’s exact test.
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increase in anatomical success is 268 eyes in each group
and recruitment of such a large number of patients may
not be feasible. We did not include eyes with other
complications of PDR such as non-clearing vitreous
hemorrhage. Additional studies with larger number of
patients, and possibly using multiple injections or higher
doses are needed to further elucidate the effects of MTX as
an adjunct in the surgical management of PDR.
Summary
What was known before
K Retinal re-detachment associated with fibrovascular
proliferation or proliferative vitreoretinopathy (PVR) is a
major cause of failure of the surgery for advanced
proliferative diabetic retinopathy (PDR).
K Inflammatory cytokines and growth factors increase in
both PVR and PDR.
What this study adds
K Intra-silicone injection of methotrexate at the end of
vitrectomy for retinal detachment associated with severe
proliferative diabetic retinopathy did not reduce the risk of
postoperative retinal detachment due to the fibrous or
fibrovascular proliferations.
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